California Supreme Court rejects claim that Gilead must fast-track safer HIV drug

Thousands of patients sued Gilead Sciences, alleging the company was negligent for delaying a safer HIV medicine and that they suffered kidney injury and bone loss from the older drug.

The California Supreme Court, in a 6-to-1 decision, overturned a lower appellate ruling and held that Gilead cannot be held liable for a legal “duty to innovate,” siding with the company.

The ruling eases fears that drug‑development choices could be driven by liability concerns, but industry observers note it underscores the potential for future lawsuits to shape pipeline strategies.

While the decision does not affect any drug approvals, it may influence how companies assess legal risk in product development and could shape future litigation tactics.